Piet Dirix1,2, Sofie Vingerhoedt3, Steven Joniau4, Ben Van Cleynenbreugel4, Karin Haustermans3. 1. Department of Radiation Oncology, Leuvens Kankerinstituut (LKI), University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium. piet.dirix@gza.be. 2. Department of Radiation Oncology, Iridium Cancer Network, GZA St Augustinus Hospital, Oosterveldlaan 24, Wilrijk (Antwerp), Antwerp, Belgium. piet.dirix@gza.be. 3. Department of Radiation Oncology, Leuvens Kankerinstituut (LKI), University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium. 4. Department of Urology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.
Abstract
PURPOSE: The aim of this study was to evaluate hematuria-free survival as well as acute and late toxicity after hypofractionated palliative radiotherapy for bladder cancer. METHODS AND MATERIALS: Between September 2004 and January 2013, 44 patients with biopsy-proven urothelial carcinoma of the bladder were irradiated according to a palliative schedule to a total dose of 34.5 Gy in six fractions of 5.75 Gy given once a week. RESULTS: After a mean follow-up of 10 months, 91% of patients were still hematuria free, with a mean hematuria-free survival of 13 months. Severe (≥ grade 3) acute and late urinary toxicity was observed in 9 and 19% of patients, respectively. CONCLUSION: This hypofractionated radiotherapy schedule appears to result in acceptable toxicity and manages successful and long-term palliation of hematuria in most patients.
PURPOSE: The aim of this study was to evaluate hematuria-free survival as well as acute and late toxicity after hypofractionated palliative radiotherapy for bladder cancer. METHODS AND MATERIALS: Between September 2004 and January 2013, 44 patients with biopsy-proven urothelial carcinoma of the bladder were irradiated according to a palliative schedule to a total dose of 34.5 Gy in six fractions of 5.75 Gy given once a week. RESULTS: After a mean follow-up of 10 months, 91% of patients were still hematuria free, with a mean hematuria-free survival of 13 months. Severe (≥ grade 3) acute and late urinary toxicity was observed in 9 and 19% of patients, respectively. CONCLUSION: This hypofractionated radiotherapy schedule appears to result in acceptable toxicity and manages successful and long-term palliation of hematuria in most patients.
Authors: Enrico Pira; Giorgio Piolatto; Eva Negri; Canzio Romano; Paolo Boffetta; Loren Lipworth; Joseph K McLaughlin; Carlo La Vecchia Journal: J Natl Cancer Inst Date: 2010-06-14 Impact factor: 13.506
Authors: Neal D Freedman; Debra T Silverman; Albert R Hollenbeck; Arthur Schatzkin; Christian C Abnet Journal: JAMA Date: 2011-08-17 Impact factor: 56.272
Authors: Nicholas D James; Syed A Hussain; Emma Hall; Peter Jenkins; Jean Tremlett; Christine Rawlings; Malcolm Crundwell; Bruce Sizer; Thiagarajan Sreenivasan; Carey Hendron; Rebecca Lewis; Rachel Waters; Robert A Huddart Journal: N Engl J Med Date: 2012-04-19 Impact factor: 91.245
Authors: W U Shipley; D S Kaufman; E Zehr; N M Heney; S C Lane; H K Thakral; A F Althausen; A L Zietman Journal: Urology Date: 2002-07 Impact factor: 2.649
Authors: Kavita V Dharmarajan; Shayna E Rich; Candice A Johnstone; Lauren M Hertan; Randy Wei; Lauren E Colbert; Joshua A Jones; Arif H Kamal; Christopher A Jones Journal: J Palliat Med Date: 2018-02-12 Impact factor: 2.947
Authors: Lucas Gomes Sapienza; Matthew Stephen Ning; Anuja Jhingran; Lilie L Lin; Caio Raposo Leão; Bruna Bueno da Silva; Antônio Cássio de Assis Pellizzon; Maria José Leite Gomes; Glauco Baiocchi Journal: Clin Transl Radiat Oncol Date: 2018-11-22